These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 8147298

  • 1. Differences in clot lysis among patients demonstrated in vitro with three thrombolytic agents (tissue-type plasminogen activator, streptokinase and urokinase).
    Musselman DR, Tate DA, Oberhardt BJ, Abruzzini AF, Blauwet MB, Koch G, Dehmer GJ.
    Am J Cardiol; 1994 Mar 15; 73(8):544-9. PubMed ID: 8147298
    [Abstract] [Full Text] [Related]

  • 2. Comparison of thrombolytic, fibrinolytic, and fibrinogenolytic properties of tissue plasminogen activator, streptokinase, single-chain urokinase, high molecular weight and low molecular weight urokinase in human plasma in vitro.
    Samama M, Nguyen G, Desnoyers P, Lourenco DM, Fretault J, Horellou MH, Conard J, Szwarcer E, Verdy E, Vahanian A.
    Fundam Clin Pharmacol; 1988 Mar 15; 2(6):509-23. PubMed ID: 3149257
    [Abstract] [Full Text] [Related]

  • 3. Impairment of fibrinolysis by streptokinase, urokinase and recombinant tissue-type plasminogen activator in the presence of radiographic contrast agents.
    Dehmer GJ, Gresalfi N, Daly D, Oberhardt B, Tate DA.
    J Am Coll Cardiol; 1995 Apr 15; 25(5):1069-75. PubMed ID: 7897118
    [Abstract] [Full Text] [Related]

  • 4. In vitro simulation of therapeutic thrombolysis with microtiter plate clot-lysis assay.
    Stief TW.
    Clin Appl Thromb Hemost; 2006 Jan 15; 12(1):21-32. PubMed ID: 16444431
    [Abstract] [Full Text] [Related]

  • 5. Accelerated thrombolysis. In vitro evaluation of agents and methods of administration.
    Bookstein JJ, Saldinger E.
    Invest Radiol; 1985 Oct 15; 20(7):731-5. PubMed ID: 2933363
    [Abstract] [Full Text] [Related]

  • 6. [New thrombolytic agents in myocardial infarction].
    Charbonnier B, Lang M, Brochier M.
    Arch Mal Coeur Vaiss; 1987 Nov 15; 80(12):1785-91. PubMed ID: 3128222
    [Abstract] [Full Text] [Related]

  • 7. Potentiation by Lys-plasminogen of clot lysis by single or two chain urokinase-type plasminogen activator or tissue-type plasminogen activator.
    Watahiki Y, Scully MF, Ellis V, Kakkar VV.
    Thromb Haemost; 1989 Jun 30; 61(3):502-6. PubMed ID: 2508259
    [Abstract] [Full Text] [Related]

  • 8. Age-related differences in a clot lysis assay after adding different plasminogen activators in a plasma milieu in vitro.
    Ries M, Zenker M, Klinge J, Keuper H, Harms D.
    J Pediatr Hematol Oncol; 1995 Aug 30; 17(3):260-4. PubMed ID: 7620925
    [Abstract] [Full Text] [Related]

  • 9. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
    Collen D, De Cock F, Demarsin E, Lijnen HR, Stump DC.
    Thromb Haemost; 1986 Aug 20; 56(1):35-9. PubMed ID: 3095946
    [Abstract] [Full Text] [Related]

  • 10. New developments in thrombolytic therapy.
    Collen D, Gold HK.
    Adv Exp Med Biol; 1990 Aug 20; 281():333-54. PubMed ID: 2129372
    [Abstract] [Full Text] [Related]

  • 11. A bleeding model in rabbits demonstrate fresh clot selectivity for a genetically engineered variant of tissue-type plasminogen activator and for streptokinase.
    Wikström K, Mattsson C, Pohl G.
    Thromb Res; 1993 May 01; 70(3):217-24. PubMed ID: 8392227
    [Abstract] [Full Text] [Related]

  • 12. [Thrombolytic drugs in acute myocardial infarct].
    Ambrosioni E, Degli Esposti D.
    Cardiologia; 1991 Dec 01; 36(12 Suppl 1):395-402. PubMed ID: 1841796
    [Abstract] [Full Text] [Related]

  • 13. Differential effects of activation of prothrombin by streptokinase compared with urokinase and tissue-type plasminogen activator (t-PA).
    Eisenberg PR, Miletich JP, Sobel BE, Jaffe AS.
    Thromb Res; 1988 Jun 01; 50(5):707-17. PubMed ID: 3137687
    [Abstract] [Full Text] [Related]

  • 14. Comparison of streptokinase, urokinase, and recombinant tissue plasminogen activator in an in vitro model of venous thrombolysis.
    Ouriel K, Welch EL, Shortell CK, Geary K, Fiore WM, Cimino C.
    J Vasc Surg; 1995 Nov 01; 22(5):593-7. PubMed ID: 7494361
    [Abstract] [Full Text] [Related]

  • 15. Coronary thrombolysis with clot-selective plasminogen activators.
    Collen D, Bounameaux H.
    Herz; 1986 Feb 01; 11(1):9-15. PubMed ID: 3082731
    [Abstract] [Full Text] [Related]

  • 16. Depletion of plasminogen in vitro or during thrombolytic therapy limits fibrinolytic potential.
    Onundarson PT, Francis CW, Marder VJ.
    J Lab Clin Med; 1992 Jul 01; 120(1):120-8. PubMed ID: 1613318
    [Abstract] [Full Text] [Related]

  • 17. [Thrombolytic agents: efficacy in relation to evolution time and dose].
    García Frade LJ, Torrado MC, Loren M, Navarro JL.
    Rev Clin Esp; 1989 Feb 01; 184(2):75-9. PubMed ID: 2502822
    [Abstract] [Full Text] [Related]

  • 18. Streptokinase, urokinase, and tissue plasminogen activator: pharmacokinetics, relative advantages, and methods for maximizing rates and consistency of lysis.
    Maizel AS, Bookstein JJ.
    Cardiovasc Intervent Radiol; 1986 Feb 01; 9(5-6):236-44. PubMed ID: 3100038
    [Abstract] [Full Text] [Related]

  • 19. In vitro comparison of fibrinolytic activity of plasminogen activators using a thrombelastographic method: in vivo evaluation of the B-chain-streptokinase complex in the dog model using pre-titered doses.
    Summaria L, Sandesara J, Yang G, Vagher JP, Caprini JA.
    Thromb Haemost; 1986 Aug 20; 56(1):71-9. PubMed ID: 2946093
    [Abstract] [Full Text] [Related]

  • 20. Which thrombolytic agent should one choose?
    Topol EJ.
    Prog Cardiovasc Dis; 1991 Aug 20; 34(3):165-78. PubMed ID: 1947122
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.